NEWS

February 02nd, 23
Social Survey Research Information Co., Ltd.

PatientsMap 2022 US version now available

Pfizer leads in reaching physicians;
Takeda is at the top among Japanese companies.

Social Survey Research Information Co., Ltd. and M3, Inc. conducted an analysis of manufacturers' activities based on the PatientsMap 2022 US version, which went on sale at the end of December 2022.

The survey asked about the status of activities, namely "awareness of sales rep visits," "awareness of online meetings," and "awareness of e-detailing."
(Table 1) shows the top 10 manufacturers in terms of awareness rate for each category, and (Table 2) shows the ranking of Japanese companies in the U.S.

In the U.S., Pfizer, Abbott, and AstraZeneca ranked high in each category. The awareness rates of sales rep visits and e-detailing were about the same among these top manufacturers.
With regard to the awareness of online meetings, Pfizer (8%) and Abbott (7%) ranked at the top in the U.S., which was only about half that of sales rep visits.
In the U.S., Pfizer topped the list at 33%, which was followed by Abbott at 31%, AstraZeneca at 29%, Merck at 25%, and AbbVie at 24% in terms of reaching physicians using one of these three methods.

Looking at Japanese companies in the U.S., Takeda, Astellas, and Otsuka Pharmaceutical were in higher ranks, in this order, in terms of all categories.
Takeda has reached 13% of physicians using one of these three methods, and the percentages for Astellas and Otsuka Pharmaceutical were 8% and 6%, respectively. Takeda ranked 17th out of the 54 companies surveyed, which was the highest among the Japanese companies.

It will be necessary to pay attention to changes in how manufacturers will utilize "sales rep visits," "online meetings," and "e-detailing" in anticipation of "coexisting with COVID-19" in the future.

(Table 1) U.S. manufacturer activities: Rank among 54 companies surveyed.
n=6085
Awareness of sales rep visitsAwareness of online meetingsAwareness of e-detailingAny of the methods
rankManufacturersManufacturersManufacturersManufacturers
1Abbott17.8%Pfizer8.2%Pfizer16.7%Pfizer32.5%
2Pfizer17.3%Abbott7.2%Abbott14.6%Abbott31.2%
3AZ15.5%AZ6.8%AZ14.3%AZ29.2%
4AbbVie14.7%AbbVie6.0%J&J12.7%Merck25.0%
5Merck13.5%Merck5.9%Merck12.4%AbbVie24.3%
6Eli Lilly13.3%J&J5.7%Eli Lilly11.6%J&J23.9%
7GSK12.3%Eli Lilly5.7%GSK10.8%Eli Lilly23.7%
8J&J11.9%GSK5.6%AbbVie10.4%GSK22.5%
9Allergan11.5%Allergan5.3%Moderna9.6%Allergan20.7%
10Sanofi11.0%Sanofi5.3%Allergan9.4%Sanofi20.0%
(Table 2) Japanese company activities in the U.S.: Rank among 54 companies surveyed.
n=6085
Awareness of sales rep visitsAwareness of online meetingsAwareness of e-detailingAny of the methods
rankManufacturersrankManufacturersrankManufacturersrankManufacturers
17Takeda6.5%16Takeda3.4%22Takeda5.9%17Takeda12.5%
27Astellas3.3%33Astellas1.8%31Astellas4.1%31Astellas8.1%
37Otsuka2.2%36Otsuka1.7%40Otsuka3.2%37Otsuka6.0%
38Daiichi Sankyo2.2%44Daiichi Sankyo1.3%41Eisai3.1%38Daiichi Sankyo5.9%
42Eisai1.7%45Eisai1.3%42Daiichi Sankyo3.0%44Eisai5.5%
49Takeda Oncology1.1%48Takeda Oncology1.2%47Takeda Oncology2.8%47Takeda Oncology4.6%
52Mitsubishi Tanabe0.8%50Mitsubishi Tanabe1.0%50Mitsubishi Tanabe2.6%51Mitsubishi Tanabe3.9%

What is PatientsMap?
PatientsMap is a large database that surveys, with the cooperation of physicians, about 400 diseases in terms of physician coverage, number of patients, unmet medical needs (diseases for which new drugs are desired, reasons for wanting new drugs, and percentage of patients for whom administering new drugs would be considered), and the activities of real sales reps (in-person) and e-detailing activities of pharmaceutical companies. The same survey frame has been used continuously for more than 10 years since 2010.

Overview of PatientsMap 2022 United States of America Version (2022US)

The PatientsMap 2022US conducted a study on 38,000 doctors who are members of M3 Global Research.
Target respondents: : M3 Global Research member doctors
Method : Online survey
Fieldwork period : December 27, 2022 to January 24, 2022
Sample size collected : 6,085 samples
Number of conditions surveyed : 410 diseases
Survey item: : Total number of patients (in the past month)
Number of patients seen by condition (in the past month)
Number of patients who were prescribed drugs by condition (in the past month)
Need for new therapy
Manufacturers that you have had a face-to-face meeting with one of their sales reps (in the past month)
Manufacturers that you have had a remote meeting with one of their sales reps (in the past month)
Manufacturer that have provided you with information via the Internet (in the past month)
Reliable manufacturers

Contact Information

Social Survey Research Information Co., Ltd.
e-mail:patientsmap@ssri.com

Social Survey Research Information Co., Ltd.

Established April 1982
Capital 27 million JPY
President & CEO Takashi Makita
Number of employees 137
Location Head Office
NMF Shinjuku East Bldg. 2F, 3F
10-5 Tomihisacho, Shinjuku-ku, Tokyo 162-0067 JAPAN
Osaka office
Daimei Bldg. 4F, 4-6-3 Hirano-cho, Chuo-ku, Osaka 541-0046 JAPAN
Affiliate companies PD Research Co., Ltd.
MDB Co.
SSRI China Co., Ltd. (overseas subsidiary)
SSRI Asia Pacific Co., Ltd. (overseas subsidiary)
HIMA Research (overseas affiliate)
URL https://www.ssri.com/

M3, Inc.

Established September 2000
Capital 29.129 billion JPY (as of March 31, 2022)
Representative Director Itaru Tanimura
Number of employees, consolidated 9,384 (as of March 31, 2022)
Location Akasaka Intercity 10F 1-11-44 Akasaka, Minato-ku, Tokyo
URL https://corporate.m3.com/
scroll top